Literature DB >> 17384256

Capacitation and acrosome reaction in nonapoptotic human spermatozoa.

Sonja Grunewald1, Thomas Baumann, Uwe Paasch, Hans-Juergen Glander.   

Abstract

Capacitation and acrosome reaction (AR) of human spermatozoa are prerequisites for fertilization. Annexin-V-MACS is able to separate apoptotic from nonapoptotic sperm on the basis of their externalization of phosphatidylserine (EPS). The nonapoptotic (EPS-) fraction is characterized by the lowest amounts of membrane alterations, caspase activation, disrupted mitochondrial potential, and DNA fragmentation. The aim of our study was to investigate the separation effect of Annexin-V-MACS on capacitation and AR in nonapoptotic sperm. Semen specimens from 10 healthy donors were separated into 2 samples each, one was left untreated (control) and the second was subjected to Annexin-V-MACS. Two aliquots of both, the control as well as the EPS- fraction after Annexin-V-MACS, were incubated in HTF at 37 degrees C, 5% CO2 for 3 h either with 3% BSA (capacitation) or without additives. Capacitation was monitored by tyrosine phosphorylation (TyrP) using Western blot technique. AR was determined by labeling with CD46-FITC before and after stimulation with calcium-ionophore A23187, followed by flow cytometric evaluation of the percentage of CD46+ sperm. Densitometric analyses of the 105-kDa and 80-kDa bands of the TyrP Western blots demonstrated highest TyrP in the capacitated EPS- aliquots. There was no difference in spontaneous AR in all groups. AR was best inducible in EPS-negative sperm after capacitation. Nonapoptotic human spermatozoa with intact plasma membranes are characterized by superior ability to capacitate and consequently by maximum potential to perform AR after stimulation. Selection of EPS-negative sperm may be of advantage for assisted reproduction in order to prepare the sperm subpopulation with the highest fertilizing potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17384256     DOI: 10.1196/annals.1378.015

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Density gradient centrifugation before or after magnetic-activated cell sorting: which technique is more useful for clinical sperm selection?

Authors:  M Tavalaee; M R Deemeh; M Arbabian; M H Nasr-Esfahani
Journal:  J Assist Reprod Genet       Date:  2011-12-15       Impact factor: 3.412

2.  Magnetic-activated cell sorting of non-apoptotic spermatozoa improves the quality of embryos according to female age: a prospective sibling oocyte study.

Authors:  Martin Stimpfel; Ivan Verdenik; Branko Zorn; Irma Virant-Klun
Journal:  J Assist Reprod Genet       Date:  2018-06-27       Impact factor: 3.412

3.  Evaluation of ubiquitin and annexin V in sperm population selected based on density gradient centrifugation and zeta potential (DGC-Zeta).

Authors:  M Zarei-Kheirabadi; E Shayegan Nia; M Tavalaee; M R Deemeh; M Arabi; M Forouzanfar; Gh R Javadi; M H Nasr-Esfahani
Journal:  J Assist Reprod Genet       Date:  2011-12-20       Impact factor: 3.412

4.  Removal of spermatozoa with externalized phosphatidylserine from sperm preparation in human assisted medical procreation: effects on viability, motility and mitochondrial membrane potential.

Authors:  Corinne de Vantéry Arrighi; Hervé Lucas; Didier Chardonnens; Ariane de Agostini
Journal:  Reprod Biol Endocrinol       Date:  2009-01-08       Impact factor: 5.211

5.  Sperm midpiece apoptotic markers: impact on fertilizing potential in in vitro fertilization and intracytoplasmic sperm injection.

Authors:  Joanna Talarczyk-Desole; Małgorzata Kotwicka; Magdalena Jendraszak; Leszek Pawelczyk; Marek Murawski; Piotr Jędrzejczak
Journal:  Hum Cell       Date:  2016-01-20       Impact factor: 4.174

6.  17β-estradiol modifies human spermatozoa mitochondrial function in vitro.

Authors:  Malgorzata Kotwicka; Izabela Skibinska; Magdalena Jendraszak; Piotr Jedrzejczak
Journal:  Reprod Biol Endocrinol       Date:  2016-08-26       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.